



SUPPLEMENTAL FIGURE S1




SUPPLEMENTAL FIGURE S2




SUPPLEMENTAL FIGURE S3


A pAAV-CBA-eGFP-2A-hTau40 Δ K280



B pAAV-CBA-eGFP-2A-hTau40 Δ K280-2P



SUPPLEMENTAL FIGURE S4



1 **Supplementary figures**

2 **SuppFig. S1: Expression of hTau in 24-month-old tTA-EC/Tau^{ΔK} and tTA-EC/Tau^{ΔK-PP} mice.**

3 Immunolabeling of hTau (human-specific Tau antibody HT7) in horizontal brain sections shows that in
4 both pro-aggregant tTA-EC/Tau^{ΔK} and anti-aggregant tTA-EC/Tau^{ΔK-PP} mice the expression of hTau
5 remains restricted to EC neurons and their axons of the perforant path, up to the molecular layer of the
6 DG. No trans-synaptic spreading of Tau protein to DG granule cells was observed, as we did not detect
7 HT7+ cells in brain regions other than the EC. WT mice (left panel) did not express hTau. Scale bar: 200
8 μm (overview images); 50 μm (close-up images).

9

10 **SuppFig. S2: Expression of Tau with pathological conformation in 24-month-old tTA-EC/Tau^{ΔK}**
11 **mice.**

12 Immunolabeling of misfolded Tau (conformational Tau antibody MC1) in horizontal brain sections detects
13 Tau with a pathological conformation only in EC neurons of pro-aggregant tTA-EC/Tau^{ΔK} mice. The
14 occurrence of MC1+ Tau remains restricted to EC neurons and their axons of the perforant path, up to the
15 molecular layer of the DG. These results support observations at earlier time points (e.g. 12-month-old
16 mice, Fig. 3) and in previous studies (23), confirming that Tau pathology, even in aged mice, is restricted
17 to the EC and perforant pathway and does not propagate to other cell layers. Anti-aggregant tTA-
18 EC/Tau^{ΔK-PP} and WT mice do not have Tau with pathological conformation. Scale bar: 200 μm (overview
19 images); 50 μm (close-up images).

20

21 **SuppFig. S3: Plasmid maps of adeno-associated viruses (AAVs) used in the study.**

22 **(A)** pAAV-CBA-eGFP-2A-hTau40^{ΔK280}, for the expression of pro-aggregant full-length mutant human Tau
23 (2N4R) with the ΔK280 mutation.

24 **(B)** pAAV-CBA-eGFP-2A-hTau40^{ΔK280-2P} for the expression of anti-aggregant full length mutant human
25 Tau with the ΔK280 mutation and two beta-breaking prolines.

26

27 **SuppFig. S4: Trans-synaptic spreading of hTau protein in WT and TKO mice injected with**
28 **AAV/Tau^{ΔK} or AAV/Tau^{ΔK-PP} 3 months p.i.**

29 **(A+B)** Immunolabeling of hTau (antibody TauY9) in brain sections revealed the presence of hTau positive
30 cells in DG, CA3 and CA1 regions of WT mice injected with pro-aggregant AAV/Tau^{ΔK} and AAV/Tau^{ΔK-PP}.
31 hTau recipient cells (GFP-/hTau+) are indicated with arrowheads.

32 **(C+D)** Immunolabeling of hTau (antibody TauY9) in brain sections revealed the presence of hTau positive
33 cells in DG, CA3 and CA1 regions of TKO mice injected with pro-aggregant AAV/Tau^{ΔK} and AAV/Tau^{ΔK-}
34 ^{PP}. hTau recipient cells (GFP-/hTau+) are indicated with arrowheads. Scale bar: 100 μm (overview
35 images); 20 μm (higher magnification images).

36